Citations

Clear

3042 citation(s) found for "Kumar, S".

Aortic Dimensions in a South Asian Population: Establishing Normative Data and Implications for Clinical Practice
Rajbanshi, Bijoy G. , Kayastha, Bhuwan, KC, Sangam, Khadka, Pralaya , Joshi, Dharmendra , Shrestha, Malakh , Mestres, Carlos A., Ghimire, Ram Kumar , Shrestha, Malakh L, Biswakarma, Gangaram, C., Sangam K. , Mestres, Carlos A

Mayo Clinic

AORTA | January 15, 2026 | Volume: 13 | Issue: 05/06 | Pages: 094-100

10.1055/a-2776-6270 | PMID 41534861 Get It

Abstract Diameter of the aorta is a significant contributor and predictor for complications and a fundamental parameter for intervention. It is recognized that age, sex, and ethnicity play a role in aortic size. We thus sought to determine the normal dimensions among our population. A retrospective analysis of images was done of all polytrauma patients admitted between January 2018 and December 2022 who underwent protocolized noncontrast computed tomography of the chest and abdomen to measure the aortic diameter at established reference points. There were 513 patients; the mean age was 36.5 ± 14.6 (range: 18–86), and 382 (74.5%) were males. Aortic dimensions at sinus, mid-ascending, arch, descending, suprarenal, and infrarenal aorta were 30.7 ± 3.8, 29.3 ± 4.5, 24.9 ± 3.3, 20.1 ± 3.0, 19.4 ± 2.9, and 15.3 ± 2.2, respectively. Age demonstrated a positive correlation to the diameter at the ascending, descending, and infrarenal aorta (r = 0.58, p = 0.001 [95% confidence interval, CI = 0.519; 0.634]; r = 0.69, p = 0.001 [95% CI = 0.641; 0.732]; r = 0.57, p = 0.001 [95% CI = 0.509; 0.626]) along with the length of the ascending aorta (r = 0.420, p = 0.001 [95% CI = 0.345; 0.488]; r = 0.536, p = 0.001 [95% CI = 0.471; 0.595]; r = 0.476, p = 0.001 [95% CI = 0.406; 0.540), respectively. There was a positive correlation of aortic diameters to body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP). Females had smaller dimension at the reference points, but without any statistical significance. There were 50 (9.8%) patients with bovine aortic arch and 10 (1.9%) with separate origin of left vertebral artery. Normal values of the diameter of the aorta for a South Asian population are provided. Diameter is affected by age, length of the ascending aorta, BMI, SBP, and DBP. This study suggests that the aorta size is smaller in the South Asian population than the referenced Western population, more significantly for distal descending and abdominal aorta and that ethnicity plays a role in determining aortic dimensions.
Efficacy and safety of trastuzumab deruxtecan in HER2-positive advanced gastric and gastroesophageal junction cancers: A meta-analysis of real-world studies and clinical trials.
Batra, Nitya, Ammakola, Yagnapriya, Mishra, Rahul, Deshmukh, Indraneel, Chitkara, Akshit , Syal, Arshi , Arya, Yajur , Singh, Rohit Kumar , Sukaina, Mahnoor , Ammakola, Yagnapriya, Mahadevia, Himil , Jatwani, Karan , Singh, Rohit, Khosla, Atulya Aman

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 402-402

10.1200/jco.2026.44.2_suppl.402 Get It

402 Background: Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody-drug conjugate (ADC) with a cytotoxic payload. TDXd was approved in 2021 to be used in advanced gastric or GEJ cancers. Although given the recent approval, real-world evidence on efficacy and safety is limited. We sought to evaluate the efficacy and safety of T-DXd through a combined meta-analysis of clinical trials and real-world studies. Methods: A comprehensive search was conducted across PubMed, Embase, Scopus, and Clinicaltrials.gov databases. The original studies evaluating T-DXd in patients with metastatic/recurrent gastric/gastroesophageal junction (GEJ) cancers were included in the analysis. The pooled objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and the incidence of adverse events (AEs) were analyzed. A random-effects model was used for meta-analysis, and the heterogeneity of the data was evaluated by Chi-sq Q test and the I 2 statistic using OpenMeta [Analyst] (Tufts Medical Center, Boston, MA, USA). Results: This meta-analysis incorporated 8 studies (3 phase II clinical trials, 5 retrospective studies) comprising 915 patients with advanced HER2-positive gastric/GEJ cancer. The median patient age was 66.5 years (range: 27–89), with 75.4% males, 70.4% Asian, and 29.0% Caucasians. 77.9% had an ECOG performance status of 0–1, while 21.8% had ECOG ≥2. Histologically, 53.6% had intestinal and 22.9% diffuse-type adenocarcinoma. HER2 overexpression (IHC3+) was observed in 75.8% of evaluable cases, and 22.4% were IHC2+/FISH positive. 77.6% had primary gastric and 22.4% GEJ tumors. The median line of therapy was 3 (range: 2–11), with prior immune checkpoint inhibitor use in 31.8% and prior surgery in 44.5% .The pooled ORR was 47.7% (95% CI 43.0-52.4%) and DCR was 82.50% (79.40%–85.72%); PFS and OS were 4.92 and 9.86 months, respectively. Safety analysis revealed grade ≥3 AEs in 48.2% of patients, neutropenia (24.5%) being the most common. Treatment discontinuation due to adverse events occurred in 12.2%, and dose reductions were required in 21.5%. Patient-reported outcomes were not assessed in any of the studies. Conclusions: Our meta-analysis, encompassing both clinical trials and real-world data, confirms the encouraging efficacy of T-DXd in gastric/GEJ cancers, with a pooled ORR of 47.7% and a median PFS of 4.92 months, and supports its use as an early-line treatment in this challenging disease landscape. This analysis also highlights the significant incidence of grade ≥3 AEs, particularly neutropenia, which necessitates vigilant monitoring and proactive management. Future research should focus on optimizing patient selection, exploring combination therapies, and refining dosing strategies to maximize clinical benefit while mitigating toxicity.
Physical activity and molecular residual disease (MRD) in stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.
Ma, Chao, Shi, Qian, Nowak, Jonathan Andrew, Pederson, Levi , Twombly, Tyler S., Zhao, Melissa , Shergill, Ardaman , Kumar, Pankaj, Couture, Félix , Kuebler, J. Philip , Krishnamurthi, Smitha S., Tan, Benjamin, Ogino, Shuji, Brown, Justin, Jurdi, Adham A., Af, Shields, Meyerhardt, J., Zhang, George Q. , Shi, Qian , Nowak, Jonathan A. , Väyrynen, Juha P. , Takashima, Yasutoshi , Kumar, Pankaj , Krishnamurthi, Smitha , Ogino, Shuji , Jurdi, Adham Adel

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 163-163

10.1200/jco.2026.44.2_suppl.163 Get It

163 Background: Being physically inactive is an independent predictor of poor outcomes in patients with stage III colon cancer. Whether physical activity can mitigate the oncologic risk of postoperative MRD is unknown. Methods: We concluded a post hoc analysis of a phase III trial evaluating celecoxib vs. placebo and 3 vs. 6 months of adjuvant chemotherapy in patients with resected stage III colon cancer. Self-reported physical activity was assessed in standardized measures of metabolic equivalent hours per week (MET-h/wk) at 2 timepoints: 1) midway through and 2) 6 months after completing adjuvant chemotherapy, modeled as a time-weighted average. MRD was determined via a clinically validated, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera, Natera, Inc.). Disease-free survival (DFS) and overall survival (OS) were estimated using flexible parametric survival models. Results: Among 763 patients (median follow-up 6.0 years), 24% were highly active (≥18 MET-h/wk) and 32% were inactive (<3 MET-h/wk); 18% were ctDNA positive. Adjusting for covariates, DFS improved in patients who were ctDNA negative and moderately active (Ref: inactive; 3-17.9 MET-h/wk; HR=0.62, 95% CI [0.40-0.97]) or highly active (HR = 0.53 [0.30-0.94]). No benefit was seen among patients who were ctDNA positive (Ref: inactive; moderately active: HR = 1.20 [0.75-1.92]; highly active: HR=0.83 [0.45-1.54]). The interaction was not significant (Pint=0.269). Physical activity did not impact OS regardless of ctDNA status. The interaction of physical activity and adjuvant celecoxib use is shown in Table. Conclusions: Among patients who were ctDNA negative, physical activity was associated with improved DFS, and may demonstrate increased survival benefit alongside adjuvant celecoxib. The additive effects of both interventions were inconclusive among those who were ctDNA positive. Support: U10CA180821, U10CA180882, U24CA196171; https://acknowledgments.alliancefound.org; Natera, Pfizer; NCT01150045. Disease-free survival by physical activity level and celecoxib use, stratified by ctDNA status. 3-yr event # at risk Adjusted HR (95% CI) P-value Pint ctDNA Negative 0.258 Inactive + placebo 23 182 Ref Active + placebo 17 132 0.74 (0.43-1.28) 0.283 Inactive + celecoxib 23 167 0.92 (0.57-1.48) 0.720 Active + celecoxib 10 146 0.40 (0.22-0.79) 0.007 ctDNA Positive 0.221 Inactive + placebo 26 33 Ref Active + placebo 15 20 0.96 (0.50-1.84) 0.903 Inactive + celecoxib 34 54 0.62 (0.37-1.05) 0.076 Active + celecoxib 14 29 0.34 (0.18-0.64) 0.001 ctDNA, circulating tumor DNA; HR, hazard ratio; CI, confidence interval. Active = ≥9 MET-h/week, inactive = <9 MET-h/week. Celecoxib use defined by assignment in CALGB/SWOG 80702. Models adjusted by T and N stage, age, sex, race, assigned cycles of fluorouracil, leucovorin, and oxaliplatin, KRAS and BRAF status, BMI, and Western diet.
Acute amyloid-β exposure disrupts insulin signaling in blood–brain barrier endothelial cell culture models
Nelson, D. , Swaminathan, Suresh Kumar, Seo, Hannah S., Azarin, Samira M. , Veerareddy, Vaishnavi, Azarin, Samira M. , Kalari, Krishna R., Kandimalla, Karunya K.

Mayo Clinic

No container title available | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8436616/v1 | PMID 41646305 Get It

Abstract Background Brain insulin resistance and cerebrovascular dysfunction emerge early in late-onset Alzheimer’s disease, but how amyloid-β (Aβ) disrupts insulin signaling at the cerebrovascular blood–brain barrier—a major site of insulin receptor signaling and transport into the brain—remains unclear. Methods We exposed two distinct human blood-brain-barrier endothelial cell models to soluble Aβ40 or Aβ42 for 1 h, followed by 100 nM insulin for 10 min. Protein and phosphoprotein responses were quantified by reverse-phase protein array, and differential expression was evaluated using linear models. Results Aβ40 reduced insulin-stimulated Akt activation and converted insulin’s normal inhibition of AMPK into modest stimulation. Aβ42 did not alter insulin-stimulated Akt signaling but moderately suppressed basal Akt activation. Conclusions These findings suggest that Aβ40 acutely impairs insulin signal transduction in BBB endothelial cells, supporting a model in which vascular Aβ exposure contributes directly to the early development of brain insulin resistance in AD.
P-1554. Cytokine dysregulation in Scrub typhus: Correlation with complications and disease severity
Kumar, MS Mohan, Biswal, Prof Manisha, Sharma, Nalin , singh, Rojar, Prasad, Deba, Behera, Ashish, Singla, N, Sharma, Nalin , Biswal, Manisha , Pannu, Ashok Kumar , Behera, Ashish

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1734 Get It

Abstract Background Pathogenesis of Scrub typhus (ST), a tick-borne acute zoonotic disease caused by the bacterium Orientia tsutsugamushi, involves infection of vascular endothelial cells, triggering a potent cytokine host response that causes organ damage. Methods Prospective study in a tertiary care hospital in North-west India in 30 cases of Scrub typhus. Measurements of cytokines IL-17A, INF-γ, TNF-α, IL-10, IL-6, IL-4, and IL-2 were carried out at admission in all 30 patients and a control group of 10 healthy persons using BDTM Cytometric Bead Array, BD Biosciences, San Diego, California, USA. Results Mean age of the entire cohort was 36 years, and the male-female ratio was 2:1. The most common symptoms were dyspnea 87%, altered sensorium 23%, abdominal pain 20%, decreased urine output 10% and myalgia in 10%. On clinical examination, eschar was present in 40%. Investigations revealed anemia in 80% cases, leukocytosis in 46.6%, thrombocytopenia in 90%, jaundice in 53.3% and elevated serum transaminase levels in 84% cases. Of all complications, acute respiratory distress syndrome occurred in 90% patients, acute kidney injury in 37% patients, acute meningoencephalitis syndrome in 30%, and myocarditis in 23%. The mean APACHE 2 score of the entire cohort was 12 . Multi-organ dysfunction syndrome (MODS) was seen in 67% of cases, and the overall mortality rate was 20%. On Fisher's Exact Correlation analysis, presentation with meningoencephalitis, myocarditis, systemic acidosis, and a high APACHE 2 score correlated with mortality. The serum levels of cytokines were elevated in all patients compared to the healthy control group (Table 1), but did not significantly differ between survivors and non-survivors. Furthermore, the elevated levels of TNF-α (p=0.004) and IL-10 (p=0.029) strongly correlated with multi-organ dysfunction syndrome (MODS). Conclusion In Scrub Typhus, the strong correlation of serum levels of TNF-α and IL-10 with multi-organ dysfunction syndrome (MODS) suggests their involvement in disease progression. The high prevalence of acute respiratory distress syndrome and MODS, alongside a mortality rate of 20%, highlights the critical nature of scrub typhus and the necessity for early recognition of complicated disease and intervention. Disclosures All Authors: No reported disclosures
P-1129. Microbiologically-defined Tissue Expander Infections: Evaluating risk factors for recurrence and optimal management strategies
Igwilo-Alaneme, Rita , Vijayasekaran, Aparna , Kumar, Nishant , Ravi, Vasupriya , Mazroua, Muhammad S., Stevens, Ryan W W, Shah, Aditya , Ranganath, Nischal , LeMahieu, Allison , Stevens, Ryan W.

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1323 Get It

Abstract Background In 2019, the US performed 290,000 breast reconstructions with an estimated infection rate of 3-35%. Tissue expander infections detract from desired aesthetic effects, delay adjuvant treatments, increase morbidity and mortality, and have high recurrence rates (20-40%). Little is known about risk factors for recurrent tissue expander infections, particularly the impacts of different treatment modalities. Methods We conducted a single-center retrospective cohort study of adult women post-mastectomy who developed microbiologically-proven tissue expander infection between the period of 2017 – 2024. Outcomes including 12-month infection recurrence and risk factors for recurrence were compared between surgical versus nonoperative groups, as well as between three surgical strategies (i.e., one-stage, two-stage, explantation). Unadjusted and adjusted logistic regression models were used to assess the associations between the treatment modalities and the outcomes. Univariate models assessed the relationship between the covariates of interest and infection recurrence. Results 107 patients were included, with the majority treated with combination of antibiotics and surgical therapy (Table 1). There was no significant difference in outcomes when the operative versus antibiotics alone cohorts were compared (Table 2). The odds of infection recurrence and rehospitalization in patients who underwent two-staged exchange or explantation were significantly lower when compared with the one-staged group (Table 3). Univariate modeling found severity and radiation therapy to be numerically more common in the group experiencing recurrence, with a trend towards statistical significance (Table 4). Conclusion Our study demonstrates reduced risk of recurrent tissue expander infection with two-staged exchange or explantation, compared to one-staged exchange. Though limited by small sample size, the strengths of our study include our presentation of the real-world variability of these syndromes and their management, adjustment for infection severity and other potential confounders; and the focus on microbiologically-defined infections. Disclosures All Authors: No reported disclosures
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Kumar, Shaji K., Adekola, Kehinde , Anderson, Larry , Costello, C. L., D’Angelo, Christopher R. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengass, J, Holmberg, Leona, Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Kang, Yubin , Larson, Sarah, Lee, Hans Chulhee, Liedtke, Michaela , Martin, Thomas, Omel, James, Robinson, Timothy J., Rosenberg, Aaron, Sherbenou, Daniel, Suvannasankha, Attaya, Valent, Jason , Varshavsky‐Yanovsky, Asya, Ye, J Christine, Kovach, Emily, Kumar, Rashmi , Kumar, Shaji , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Costello, Caitlin , Derman, Benjamin A. , Devarakonda, Srinivas , Hillengass, Jens, Holmberg, Leona , Kang, Yubin , Larson, Sarah, Lee, Hans C. , Rosenberg, Aaron , Sarosiek, Shayna , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovách, E

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 8, 2026 | Volume: 24 | Issue: 1 | Pages: No page available

10.6004/jnccn.2026.0001 | PMID 41671464 Get It

The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia
Zanwar, Saurabh , Abeykoon, Jithma P. , D'Sa, Shirley , Larson, Dirk R. , Colby, Colin , Durot, Eric, Kastritis, Efstathios, Uppal, Encarl , Tomkins, Oliver , Morel, Pierre , Montes, Lydia , Paludo, Jonas, Ogunbiyi, Olabisi, Cornillet‐Lefèbvre, Pascale , Rajkumar, S Vincent, Quinquenel, Anne, Gertz, Morie A, Kumar, Shaji , Dimopoulos, M, Ansell, Stephen M., Kapoor, Prashant , D’Sa, Shirley , Abeykoon, Jithma P , Roos-Weil, Damien , Larson, Dirk , Colby, Colin L , Durot, Eric , Kastritis, Efstathios , Uppal, Encarl , Tomkins, Oliver , Morel, Pierre , Mondello, Patrizia , Montes, Lydia , Paludo, Jonas , Ogunbiyi, Olabisi , Cornillet-Lefebvre, Pascale , Quinquenel, Anne , Dispenzieri, Angela , Fonseca, Rafael , Gertz, Morie A , Kumar, Shaji K , Dimopoulos, Meletios A , Treon, Steven , Castillo, Jorge J , Kapoor, Prashant , Durot, Éric , Kastritis, Efstathios , Mondello, Patrizia , Paludo, Jonas , Ailawadhi, Sikander , Sarosiek, Shayna , Rajkumar, S. Vincent , Quinquenel, Anne , Dispenzieri, Angela , Fonseca, Rafaël , Gertz, Morie A. , Dimopoulos, Meletios Α. , Ansell, Stephen M. , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

Blood Advances | January 7, 2026 | Volume: 10 | Issue: 7 | Pages: 2322-2327

10.1182/bloodadvances.2025017751 | PMID 41499755 Get It

Abstract Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in patients treated with chemoimmunotherapy remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates inconsistently with overall survival (OS), underscoring the importance of examining other surrogates. Progression of disease within 24 months (POD24), an established early end point, delineates functionally high-risk patients in other indolent lymphomas. This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. At a median follow-up of 5.9 years, 5-year PFS and OS were 65% and 87%, respectively; 5-year PFS was similar between MYD88L265P (90%) and MYD88wild-type (WT) subcohorts (64% each; P = .4). Among 89 patients with known CXCR4 status, the subcohort with CXCR4mutation (28%) had shorter PFS (median 3.3 vs 8.8 years; hazard ratio [HR], 2.8; P = .0036) and OS (HR, 2.6; P = .036) compared with CXCR4WT. POD24 occurred in 11.5% of patients who demonstrated inferior subsequent OS (5-year OS, 71% vs 86%; HR, 3.1; P = .005) and higher mortality (standardized mortality ratio [SMR], 3.7), unlike the non-POD24 group, whose mortality was comparable to the matched general population (SMR, 1.1). In conclusion, BR is effective irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Patients without POD24 represent a cohort with distinctly favorable outcome.
Glutathione synthetase deficiency: 10 years later
Bindu, B. J., Dhamija, Radhika , Ferdjallah, Asmaa , Suresh Kumar Bindu, Bharath Nair , Dhamija, Radhika

Mayo Clinic

BMJ Case Reports | January 7, 2026 | Volume: 19 | Issue: 1 | Pages: e269050

10.1136/bcr-2025-269050 | PMID 41500709 Get It

Glutathione synthetase (GSS) deficiency is an extremely rare autosomal recessive inborn error of metabolism. This metabolic disorder is caused by mutations in the GSS gene, which encodes GSS—an enzyme that catalyses the ATP-dependent conversion of γ-glutamyl-cysteine and glycine to glutathione. Low glutathione impairs the cellular antioxidant defence mechanism, leaving cells susceptible to oxidative stress and damage.
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, Lisa K., Messersmith, Hans , Hadidi, Samer S.A. Al, Banerjee, Rahul, Kumar, Shaji , Wildes, Tanya M. , Bal, Susan, Bhella, Sita , Chmielewski, Cynthia, Costello, C. L., Dabney, Raetasha, Hartley-Brown, Monique, Langerak, Alan, Martin, Thomas, Mian, Hira, Riva, Eloisa, Seth, Rahul, Subramanian, Latha, Hicks, Lisa K. , Banerjee, Rahul , Mian, Hira , Hicks, Lisa K. , Messersmith, Hans , Al Hadidi, Samer , Banerjee, Rahul , Derman, Benjamin A , Kumar, Shaji K , Wildes, Tanya , Bal, Susan , Hartley-Brown, Monique , Lipe, Brea , McCurdy, Arleigh , Mian, Hira , Riva, Eloisa , Derman, Benjamin A. , Bal, Susan , Chmielewski, Cynthia, Costello, Caitlin , Martin, Thomas, McCurdy, Arleigh , Mıkhael, Joseph

Mayo Clinic

Journal of Clinical Oncology | January 6, 2026 | Volume: 44 | Issue: 10 | Pages: 914-941

10.1200/jco-25-02587 | PMID 41494138 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To provide updated guidance regarding the therapy for multiple myeloma. METHODS ASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature. RESULTS The updated review identified a total of 161 relevant randomized trials. UPDATED RECOMMENDATIONS Daratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles. Additional information is available at www.asco.org/hematologic-malignancies-guidelines .